- £218.75bn
- £236.77bn
- $54.07bn
- 78
- 14
- 98
- 73
REG - AstraZeneca PLC - AstraZeneca divests rights for Losec to Cheplaphar
AnnouncementREG - AstraZeneca PLC - Lynparza more than doubled the time without
AnnouncementREG - AstraZeneca PLC - Lynparza improved the time women lived without
AnnouncementREG - AstraZeneca PLC - Tagrisso is the only 1st-line treatment for EGFR-
AnnouncementREG - AstraZeneca PLC - Qtrilmet recommended for approval in EU by CHMP
AnnouncementREG - AstraZeneca PLC - AstraZeneca amends collaboration with Ironwood
AnnouncementREG - AstraZeneca PLC - Imfinzi is first immunotherapy to show both
AnnouncementREG - AstraZeneca PLC - Tagrisso approved in China as a 1st-line treatment
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Detailed results from Phase III DAPA-HF trial
AnnouncementREG - AstraZeneca PLC - Brilinta reduced the risk of cardiovascular events
AnnouncementREG - AstraZeneca PLC - Anifrolumab Phase III trial meets primary endpoint
AnnouncementREG - AstraZeneca PLC - Breztri Aerosphere Phase III ETHOS trial met
AnnouncementREG - AstraZeneca PLC - Fasenra granted US Orphan Drug Designation for
AnnouncementREG - AstraZeneca PLC - AstraZeneca agrees to buy US FDA Priority Review
AnnouncementREG - AstraZeneca PLC - Roxadustat approved in China for the treatment of
AnnouncementREG - AstraZeneca PLC - Update on the Phase III NEPTUNE trial
AnnouncementREG - AstraZeneca PLC - Farxiga met primary endpoint in landmark Phase III
AnnouncementREG - AstraZeneca PLC - Directorate Change
Announcement